In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IN VIVO’s Deals Of The Month: April 2016

Executive Summary

IN VIVO’s editors pick April's most significant deals, including DalCor Pharma's big B round and a rash of NASH deals. (Article free with registration.)

You may also be interested in...



Deal Watch: NASH In The Hot Seat

Regeneron stayed busy during the past two weeks, collaborating and making an equity commitment to CRISPR gene-editing biotech Intellia and signing an immuno-oncology deal with MedImmune. Allergan bounced off the termination of its merger with Pfizer by partnering with Heptares in neurological disease.

Tobira/Dong-A Partnership Will Add DPP-4 Inhibitor For NASH Combo Therapy

California biotech acquires rights to Suganon, approved for type 2 diabetes in South Korea, while partner Dong-A gets domestic rights to NASH candidate cenicriviroc.

Allergan's Back In The (M&A) Saddle Again Post-Pfizer Breakup

CEO Brent Saunders says company now is "recharged" and "ready to go," and it ends the day announcing a partnership wth Heptares.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT003605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel